Thu, Nov 20, 2014, 10:29 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Ocata Therapeutics, Inc. Message Board

beareclawe 239 posts  |  Last Activity: 3 hours ago Member since: Dec 1, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • beareclawe beareclawe Nov 6, 2014 4:04 AM Flag

    Re: There is a special place in hell ...

    Does that include folks like YOU and fellow members/sympathizers of the rabidly optimistic, unconscionable, and conjecture-based camp ?

    : )

  • beareclawe beareclawe Nov 6, 2014 3:50 AM Flag

    Re: There is a special place in hell ...

    Have you had your maui beach filled 'sand sack' therapy session today ? Simple sand sack guru says.....

    FIGHTERPILOT Mar 27, 2012 3:38 PM
    Hate and envy
    It's not healthy. Those who suffer from this terrible condition, should consider replacing their MB posts with several hours a day punching a sand sack. You can write my ID on it or ACTC.

    : )

  • Reply to

    You MF daytraders. Go somewhere else you POS.

    by yasoocat2002 Jun 5, 2009 10:15 AM
    beareclawe beareclawe Nov 6, 2014 3:42 AM Flag

    Re: You ...

    tony_montello2003 • Nov 06, 2014 2 hours 7 minutes ago
    JMY ESEKLA DOUGLAS DALLAM using seeking alpha platform in conjunction with organized crime to short ACTC stock by selling 1 share at a time in multiple brokerage accounts to create fear and steal shares from long term holders. ESEKLA touted his 7 step process for almost a year than does a 360 and throws in the towel on the EVE of biggest peer reviewed data release in medical history for ACTC AMD/SMD MA09 theraphis which showed 17 out of 18 patients progression of the disease halted and 10 patients with visual acuity gains. It took doctors and scientists over 10 months to put this peer review article together and it took ESEKLA 10 seconds to discredit the entire study. ESEKLA timed his bash article on the eve of data release with market tanking 200 points to create a false premise to mislead ACTC investors. SEC is looking in to these 1 share trades following the data release all the way today to 11/5/2014 where hundreds of 1 shares were sold to create panic selling in ACTC shares. ESEKLA, EX Con from NY JMY and ex con from Jersey Douglas Dallam teamed up to create this panic selling in ACTC shares, JMY made up lies with 0 scientific knowledge of the Science to discredit ACTC peer reviewed Journal and went as far as to promote STEM cell AMD therapy which uses cells from aborted fetus and showed 0 efficacy in there results presented to date. STEM lead investigator has filed a law suit claiming that STEM therapy for AMD can cause deaths in patients because of the nature of cells in use. DD is just a enforcer of these 2 ESEKLA and JMY and create fear mongering by hogging up 90% of the responses on there articles and I think he is partially #$%$.
    Let it be written,
    There is a special place in hell for ESEKLA JMY DD trying to bring a company down that is trying to bring life saving therapies for patients,
    Dr. Tony Montello.

    Sentiment: Strong Buy

  • beareclawe beareclawe Nov 5, 2014 8:15 PM Flag

    Re: If you wait until FDA approval you will have missed the majority of profit opportunity in ACTC stock.

    beareclawe • Oct 18, 2014 6:00 PM
    Re: Wow, ....... been busy!
    Yes, yess, yesss........ as the anxious and desperate story stock lovers chase the elusive ACTC pot of gold at the end of a rainbow...... I'll be content with what's between the end(s) of the rainbow. : ) The trend is your friend.

    beareclawe • Oct 29, 2014 8:30 PM
    (excerpt)
    Re: To me, dwelling on past to look for this company's future is wrong.
    I'm beareclawe, and my beare thoughts are not your thoughts, neither are your ways my beare ways. As the celestial heavens are higher than the earth, so are my beare ways higher than your ways, and my beare thoughts than your thoughts. Also, I bear alone. I'm on my own side. Beareclawe's philosophy : There's no need to believe in any side. There is only yourself. The belief is in your own precision, or trading strategies.

    : )

    : )

  • beareclawe beareclawe Nov 5, 2014 2:55 PM Flag

    Re: Much work remains to be done before hESC and induced pluripotent stem cell therapies go beyond regulatory trials, but the path is now set in motion.

    : )

  • beareclawe beareclawe Nov 5, 2014 1:59 PM Flag

    Re: There is a difference between "might not be ready" and "will not be ready"!!!

    Semantics......

    Re: If the Ph 2.....

    How long did phase I last ? Now there's is phase II........ then phase III.

    ACTs Conference Call
    Wednesday, October 15, 2014
    (excerpt)
    Eddy Anglade: We are now gearing up to initiate our Phase II studies and remain committed to our previously stated goal of initiating Phase II before the end of this year. I am pleased to let you know that we have finalized our Phase II design and we're strengthening our capabilities and extending our network of trial sites to support this next phase of product development. I will now provide you with some highlights of our Phase II design and execution plan. First, we plan to start with the SMD trial in the 4th quarter of this year and will initiate the AMD trial in the first half of 2015. The Phase II Stargardt's macular degeneration trial will target an enrollment of 100 patients, and the goals of this study are to evaluate the safety and the efficacy of RPE cellular therapy. Outcome parameters will include assessment of visual function, as well as structural changes. In the first half of 2015, we will also initiate a Phase II trial of approximately 50 patients in age-related macular degeneration. The goals of this trial will be to explore the preliminary efficacy of RPE cellular therapy in AMD, as well as to optimize the concomitant immunosuppressive therapy required in the peri and post-transplantation period. We anticipate that enrollment for the 100 patient SMD study will take between 18 and 24 months, and take place in approximately 30 sites across North America and Europe. The 50 patient AMD trial will occur in approximately 10 US sites and we expect to complete enrollment by the middle of 2016.

    The Lancet, October 14, 2014
    Comment/Anthony Atala
    Human stem cell-derived retinal cells for macular diseases
    (excerpt)
    Much work remains to be done before hESC and induced pluripotent stem cell therapies go beyond regulatory trials, but the path is now set in motion.

    : )

  • Reply to

    The loud voices of the irrational words

    by nmiamisam Nov 4, 2014 2:34 PM
    beareclawe beareclawe Nov 4, 2014 3:18 PM Flag

    Re: The loud voices of the irrational words...

    How 'bout Steven Schwartz, MD ?

    npr
    Embryonic Stem Cells Restore Vision In Preliminary Human Test
    Rob Stein
    October 14, 2014

    (excerpt)

    For his part, Schwartz says he's just trying to help blind people see better. But he cautions that this work is still at a very early stage.

    "I don't want patients to come in to their doctor saying, 'Hey, I heard about the stem cells on the radio and I'd really like to get that treatment done, and what do you think?' " he says. "It's not ready. Maybe in a few years. Maybe not. We have to wait and see. The jury is way out still."

    : )

  • beareclawe beareclawe Nov 4, 2014 11:33 AM Flag

    Re: "Any treatment might not be ready for FDA approval until 2020, Dr. Lanza said."

    Tuesday, October 14, 2014
    Published study shows: ACT treatment restores some sight
    By Lisa Eckelbecker TELEGRAM & GAZETTE STAFF

    (excerpt)

    New medical treatments generally must undergo three phases of human study to demonstrate safety, proper dosing and efficacy before the Food and Drug Administration will approve them for sale. In addition to its phase 1 study in the United States, Advanced Cell has been conducting a phase 1 study of its RPE cells in patients in the United Kingdom.

    "We treated the last UK patients last month, and they also have not seen any safety issues related to the transplanted tissues themselves, either," Dr. Lanza said. Advanced Cell now hopes to launch a 100-patient, phase 2 study in Stargardt's patients by the end of the year, according to Dr. Lanza. A second, smaller phase 2 study in patients with age-related macular degeneration would follow, he said. Any treatment might not be ready for FDA approval until 2020, Dr. Lanza said.

    : )

  • beareclawe beareclawe Nov 4, 2014 11:27 AM Flag

    Re: I wish I understood why but I am without comprehension. : )

    Freddy, you know my kodiah archipelago background in intelligence. It is my area of expertise.

    : )

  • beareclawe beareclawe Nov 4, 2014 11:19 AM Flag

    Re: That's a long way down the road...

    npr
    Embryonic Stem Cells Restore Vision In Preliminary Human Test
    October 14, 2014

    (excerpt)

    For his part, Schwartz says he's just trying to help blind people see better. But he cautions that this work is still at a very early stage.

    "I don't want patients to come in to their doctor saying, 'Hey, I heard about the stem cells on the radio and I'd really like to get that treatment done, and what do you think?' " he says. "It's not ready. Maybe in a few years. Maybe not. We have to wait and see. The jury is way out still."

    : )

  • beareclawe beareclawe Nov 4, 2014 5:19 AM Flag

    Re: "Any treatment might not be ready for FDA approval until 2020, Dr. Lanza said."

    Tuesday, October 14, 2014
    Published study shows: ACT treatment restores some sight
    By Lisa Eckelbecker TELEGRAM & GAZETTE STAFF

    (excerpt)

    New medical treatments generally must undergo three phases of human study to demonstrate safety, proper dosing and efficacy before the Food and Drug Administration will approve them for sale. In addition to its phase 1 study in the United States, Advanced Cell has been conducting a phase 1 study of its RPE cells in patients in the United Kingdom.

    "We treated the last UK patients last month, and they also have not seen any safety issues related to the transplanted tissues themselves, either," Dr. Lanza said. Advanced Cell now hopes to launch a 100-patient, phase 2 study in Stargardt's patients by the end of the year, according to Dr. Lanza. A second, smaller phase 2 study in patients with age-related macular degeneration would follow, he said. Any treatment might not be ready for FDA approval until 2020, Dr. Lanza said.

    : )

  • beareclawe beareclawe Nov 4, 2014 5:11 AM Flag

    Re: Thanks for bringing that to my attention as I did not know that......

    The Lancet
    Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies
    October 15, 2014

    (excerpt)

    The oral systemic immunosuppression regimen included tacrolimus and mycophenolate mofetil 1 week before the surgical procedure and continued for 12 weeks (appendix).

    : )

  • beareclawe beareclawe Nov 3, 2014 6:48 AM Flag

    Re: Much work remains to be done before hESC and induced pluripotent stem cell therapies go beyond regulatory trials, ...

    ACTs Conference Call
    Wednesday, October 15, 2014

    (excerpt)

    Eddy Anglade: We are now gearing up to initiate our Phase II studies and remain committed to our previously stated goal of initiating Phase II before the end of this year. I am pleased to let you know that we have finalized our Phase II design and we're strengthening our capabilities and extending our network of trial sites to support this next phase of product development. I will now provide you with some highlights of our Phase II design and execution plan. First, we plan to start with the SMD trial in the 4th quarter of this year and will initiate the AMD trial in the first half of 2015. The Phase II Stargardt's macular degeneration trial will target an enrollment of 100 patients, and the goals of this study are to evaluate the safety and the efficacy of RPE cellular therapy. Outcome parameters will include assessment of visual function, as well as structural changes. In the first half of 2015, we will also initiate a Phase II trial of approximately 50 patients in age-related macular degeneration. The goals of this trial will be to explore the preliminary efficacy of RPE cellular therapy in AMD, as well as to optimize the concomitant immunosuppressive therapy required in the peri and post-transplantation period. We anticipate that enrollment for the 100 patient SMD study will take between 18 and 24 months, and take place in approximately 30 sites across North America and Europe. The 50 patient AMD trial will occur in approximately 10 US sites and we expect to complete enrollment by the middle of 2016.

    : )

  • beareclawe beareclawe Nov 3, 2014 6:41 AM Flag

    Re: Unfortunately...............

    " Any treatment might not be ready for FDA approval until 2020, Dr. Lanza said."

    Tuesday, October 14, 2014
    Published study shows: ACT treatment restores some sight
    By Lisa Eckelbecker TELEGRAM & GAZETTE STAFF

    (excerpt)

    New medical treatments generally must undergo three phases of human study to demonstrate safety, proper dosing and efficacy before the Food and Drug Administration will approve them for sale. In addition to its phase 1 study in the United States, Advanced Cell has been conducting a phase 1 study of its RPE cells in patients in the United Kingdom.

    "We treated the last UK patients last month, and they also have not seen any safety issues related to the transplanted tissues themselves, either," Dr. Lanza said. Advanced Cell now hopes to launch a 100-patient, phase 2 study in Stargardt's patients by the end of the year, according to Dr. Lanza. A second, smaller phase 2 study in patients with age-related macular degeneration would follow, he said. Any treatment might not be ready for FDA approval until 2020, Dr. Lanza said.

    "It's not ready. Maybe in a few years. Maybe not. We have to wait and see. The jury is way out still."

    October 14, 2014 6:33 PM ET
    npr
    Embryonic Stem Cells Restore Vision In Preliminary Human Test
    Rob Stein

    (excerpt)

    For his part, Schwartz says he's just trying to help blind people see better. But he cautions that this work is still at a very early stage. "I don't want patients to come in to their doctor saying, 'Hey, I heard about the stem cells on the radio and I'd really like to get that treatment done, and what do you think?' " he says. "It's not ready. Maybe in a few years. Maybe not. We have to wait and see. The jury is way out still."

    : )

  • Reply to

    O/T- Good Morning Sunday Coffee- ACTC/ Election

    by bum5353 Nov 2, 2014 7:22 AM
    beareclawe beareclawe Nov 2, 2014 4:04 PM Flag

    Re: Bottom line is that the whole representative democracy experiment has been proven by America to ultimately fail. Trouble is .......

    The kachina bear spirit informed me there are powerful, unseen supernatural forces working against the best human efforts at human rulership.

    : )

  • Reply to

    Results Summary – The Lancet, Oct. 2014

    by efficacy_20_40 Nov 1, 2014 10:25 AM
    beareclawe beareclawe Nov 2, 2014 2:06 PM Flag

    Re: Set in motion and accelerating imho, ...

    ACTs Conference Call
    Wednesday, October 15, 2014

    (excerpt)

    Eddy Anglade: We are now gearing up to initiate our Phase II studies and remain committed to our previously stated goal of initiating Phase II before the end of this year. I am pleased to let you know that we have finalized our Phase II design and we're strengthening our capabilities and extending our network of trial sites to support this next phase of product development. I will now provide you with some highlights of our Phase II design and execution plan. First, we plan to start with the SMD trial in the 4th quarter of this year and will initiate the AMD trial in the first half of 2015. The Phase II Stargardt's macular degeneration trial will target an enrollment of 100 patients, and the goals of this study are to evaluate the safety and the efficacy of RPE cellular therapy. Outcome parameters will include assessment of visual function, as well as structural changes. In the first half of 2015, we will also initiate a Phase II trial of approximately 50 patients in age-related macular degeneration. The goals of this trial will be to explore the preliminary efficacy of RPE cellular therapy in AMD, as well as to optimize the concomitant immunosuppressive therapy required in the peri and post-transplantation period. We anticipate that enrollment for the 100 patient SMD study will take between 18 and 24 months, and take place in approximately 30 sites across North America and Europe. The 50 patient AMD trial will occur in approximately 10 US sites and we expect to complete enrollment by the middle of 2016.

    : )

  • beareclawe beareclawe Nov 2, 2014 12:39 PM Flag

    Re: New medical treatments generally must undergo three phases of human study to demonstrate safety, proper dosing and efficacy before the Food and Drug Administration will approve them for sale.

    Stem Cells Grown in Lab Prior to Clinical Use as Transplantation Product Are Biological Drugs Subject to FDA Rules

    U.S. v. Regenerative Sciences, Record No. 12-5254 (U.S. Court of Appeals, District of Columbia Circuit, February 4, 2014)

    : )

  • beareclawe beareclawe Nov 2, 2014 12:35 PM Flag

    Re: New medical treatments generally must undergo three phases of human study to demonstrate safety, proper dosing and efficacy before the Food and Drug Administration will approve them for sale.

    ACTs Conference Call
    Wednesday, October 15, 2014

    (excerpt)

    Eddy Anglade: We are now gearing up to initiate our Phase II studies and remain committed to our previously stated goal of initiating Phase II before the end of this year. I am pleased to let you know that we have finalized our Phase II design and we're strengthening our capabilities and extending our network of trial sites to support this next phase of product development. I will now provide you with some highlights of our Phase II design and execution plan. First, we plan to start with the SMD trial in the 4th quarter of this year and will initiate the AMD trial in the first half of 2015. The Phase II Stargardt's macular degeneration trial will target an enrollment of 100 patients, and the goals of this study are to evaluate the safety and the efficacy of RPE cellular therapy. Outcome parameters will include assessment of visual function, as well as structural changes. In the first half of 2015, we will also initiate a Phase II trial of approximately 50 patients in age-related macular degeneration. The goals of this trial will be to explore the preliminary efficacy of RPE cellular therapy in AMD, as well as to optimize the concomitant immunosuppressive therapy required in the peri and post-transplantation period. We anticipate that enrollment for the 100 patient SMD study will take between 18 and 24 months, and take place in approximately 30 sites across North America and Europe. The 50 patient AMD trial will occur in approximately 10 US sites and we expect to complete enrollment by the middle of 2016.

    : )

  • beareclawe beareclawe Nov 2, 2014 11:46 AM Flag

    Re: ..............the science or trial results.

    " Any treatment might not be ready for FDA approval until 2020, Dr. Lanza said."

    Tuesday, October 14, 2014
    Published study shows: ACT treatment restores some sight
    By Lisa Eckelbecker TELEGRAM & GAZETTE STAFF

    (excerpt)

    New medical treatments generally must undergo three phases of human study to demonstrate safety, proper dosing and efficacy before the Food and Drug Administration will approve them for sale. In addition to its phase 1 study in the United States, Advanced Cell has been conducting a phase 1 study of its RPE cells in patients in the United Kingdom.

    "We treated the last UK patients last month, and they also have not seen any safety issues related to the transplanted tissues themselves, either," Dr. Lanza said. Advanced Cell now hopes to launch a 100-patient, phase 2 study in Stargardt's patients by the end of the year, according to Dr. Lanza. A second, smaller phase 2 study in patients with age-related macular degeneration would follow, he said. Any treatment might not be ready for FDA approval until 2020, Dr. Lanza said.

    "It's not ready. Maybe in a few years. Maybe not. We have to wait and see. The jury is way out still."

    October 14, 2014 6:33 PM ET
    npr
    Embryonic Stem Cells Restore Vision In Preliminary Human Test
    Rob Stein

    (excerpt)

    For his part, Schwartz says he's just trying to help blind people see better. But he cautions that this work is still at a very early stage. "I don't want patients to come in to their doctor saying, 'Hey, I heard about the stem cells on the radio and I'd really like to get that treatment done, and what do you think?' " he says. "It's not ready. Maybe in a few years. Maybe not. We have to wait and see. The jury is way out still."

    : )

  • Reply to

    Results Summary – The Lancet, Oct. 2014

    by efficacy_20_40 Nov 1, 2014 10:25 AM
    beareclawe beareclawe Nov 2, 2014 4:30 AM Flag

    Re: Much work remains to be done ...

    ACTs Conference Call
    Wednesday, October 15, 2014

    (excerpt)

    Eddy Anglade: We are now gearing up to initiate our Phase II studies and remain committed to our previously stated goal of initiating Phase II before the end of this year. I am pleased to let you know that we have finalized our Phase II design and we're strengthening our capabilities and extending our network of trial sites to support this next phase of product development. I will now provide you with some highlights of our Phase II design and execution plan. First, we plan to start with the SMD trial in the 4th quarter of this year and will initiate the AMD trial in the first half of 2015. The Phase II Stargardt's macular degeneration trial will target an enrollment of 100 patients, and the goals of this study are to evaluate the safety and the efficacy of RPE cellular therapy. Outcome parameters will include assessment of visual function, as well as structural changes. In the first half of 2015, we will also initiate a Phase II trial of approximately 50 patients in age-related macular degeneration. The goals of this trial will be to explore the preliminary efficacy of RPE cellular therapy in AMD, as well as to optimize the concomitant immunosuppressive therapy required in the peri and post-transplantation period. We anticipate that enrollment for the 100 patient SMD study will take between 18 and 24 months, and take place in approximately 30 sites across North America and Europe. The 50 patient AMD trial will occur in approximately 10 US sites and we expect to complete enrollment by the middle of 2016.

    : )

ACTC
6.97+0.17(+2.50%)Nov 13 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Splunk, Inc.
NasdaqGSThu, Nov 20, 2014 4:00 PM EST
GameStop Corp.
NYSEThu, Nov 20, 2014 4:00 PM EST
GoPro, Inc.
NasdaqGSThu, Nov 20, 2014 4:00 PM EST